Skip to content

Addiction: all studies

Page 370 of 857: studies 3,691 to 3,700 of 8,563, newest first. Back to the addiction overview

Research

Aesthetic chills mitigate maladaptive cognition in depression

BMC Psychiatry January 10, 2024 Abhinandan Jain, Vladimir Adrien, Pattie Maes et al. 9 citations

Abstract Background Depression is a major global health challenge, affecting over 300 million people worldwide. Current pharmacological and psychotherapeutic interventions have limited efficacy, underscoring the need for novel approaches. Emerging evidence suggests that peak emotional experiences characterized by awe, transcendence, and meaning hold promise for rapidly shifting maladaptive...

DOI: 10.1186/s12888-023-05476-3 (opens in new tab) Chills Cognition Schema genetic algorithms Clinical psychology +2

Sex Differences in Response-Contingent Cannabis Vapor Administration During Adolescence Mediate Enduring Effects on Behavioral Flexibility and Prefrontal Microglia Activation in Rats

Cannabis and Cannabinoid Research January 8, 2024 Timothy G. Freels, Sara R Westbrook, Erica Zamberletti et al.

Introduction: Cannabis is the most used illicit drug in the United States. With many states passing legislation to permit its recreational use, there is concern that cannabis use among adolescents could increase dramatically in the coming years. Historically, it has been difficult to model real-world cannabis use to investigate the causal relationship between cannabis use in adolescence and...

Aberrant salience in cannabis-induced psychosis: a comparative study

Frontiers in Psychiatry January 8, 2024 Valerio Ricci, Ilenia di Muzio, Franca Ceci et al.

Background Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can increase the risk and exacerbate the course of psychotic disorders. These could be influenced by the Aberrant Salience (AS) construct. It refers to an excess of attribution of meaning to stimuli that are otherwise regarded as neutral, thereby transform them into adverse, dangerous, or mysterious entities. This leads the...

In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin

Frontiers in Psychiatry January 8, 2024 N. Jones, Laura M. Wagner, Molly C. Pellitteri Hahn et al. 10 citations

Introduction The use of the psychedelic compound psilocybin in conjunction with psychotherapy has shown promising results in the treatment of psychiatric disorders, though the underlying mechanisms supporting these effects remain unclear. Psilocybin is a Schedule I substance that is dephosphorylated in vivo to form an active metabolite, psilocin. Psilacetin, also known as O-acetylpsilocin or...

Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq

bioRxiv (Cold Spring Harbor Laboratory) January 7, 2024 Ziran Huang, Xiaoyan Wei, Xiaobin Wang et al. 3 citations preprint

Abstract Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT 2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin on the brain are not fully...

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Current Neuropharmacology January 5, 2024 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al. 73 citations

Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review

bioRxiv (Cold Spring Harbor Laboratory) January 5, 2024 Ron Shore, K. Dobson, Nina Thomson et al. 3 citations preprint

Abstract Background and Aims Psilocybin is a psychedelic drug that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review on pre-clinical behavioural investigations of psilocybin in non-human animals to help determine the behavioural effects of psilocybin in...

5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.

International Journal of Molecular Sciences January 5, 2024 Sofía Villalba, Bruno González, Stephanie Junge et al. 9 citations

Noribogaine (noribo) is the primary metabolite from ibogaine, an atypical psychedelic alkaloid isolated from the root bark of the African shrub Tabernanthe iboga. The main objective of this study was to test the hypothesis that molecular, electrophysiological, and behavioral responses of noribo are mediated by the 5-HT2A receptor (5-HT2AR) in mice. In that regard, we used male and female,...

What is it like to be an AI bat?

Qeios January 4, 2024 D. J. Herzog, Nitsa Herzog

Consciousness is a natural phenomenon, familiar to every person. At the same time, it cannot be described in singular terms. The rise of Artificial Intelligence in recent years has made the topic of Artificial Consciousness highly debated. The paper discusses the main general theories of consciousness and their relationship with proposed Artificial Consciousness solutions. There are a number of...

Exploring the Association Between Dreams and Personality Traits

Lecture Notes in Education Psychology and Public Media January 3, 2024 Ze-Ming Zhao

This study focuses on the often-neglected aspect of 'dream attitudes,' such as participants' interest in dreams and the impact of their dreams. By examining the relationships between dreaming, attitudes toward dreams, gender, and personality traits, we aim to explore the continuity between dreaming and wakefulness from a new perspective. Specifically, we hypothesize that: (1) there are...